Bayer is trading at €53.12, up 6.20%, after its November 3 third-quarter update raised its 2026 outlook, with pharmaceuticals driving growth.
- The update reported higher sales and EBITDA.
- Bayer raised its 2026 outlook for pharmaceutical margins, group EBITDA and free cash flow, and expects lower year-end debt. Reuters also reported the raised profit outlook, citing better-than-anticipated pharmaceutical performance.
- Trading volume and activity data were not provided.